NxStage Announces Significant Increase in Nx2me Connected Health® Platform Adoption

LAWRENCE, Mass., Oct. 26, 2018 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced that the number of home hemodialysis (HHD) patients using its Nx2me Connected Health platform has increased 220% in the past year.¹

Nx2me^® is designed to enhance the connection between NxStage^® System One™ HHD patients and clinicians, and has been shown to improve patient retention and training graduation rates.  Research findings demonstrate that patients using Nx2me experienced:

• 29% lower therapy discontinuation rates due to controllable causes,² and,
• 34% reduction in technique failure, relative to match controls in patients who began using Nx2me within 3 months of initiating HHD.²

"We are really beginning to see a shift toward using innovative telehealth solutions to help improve patient outcomes with home dialysis," said Dr.  Michael Kraus, Associate Chief Medical Officer for NxStage. "Nx2me is an intuitive tool to support and proactively engage with home hemodialysis patients. The platform's impressive performance data will continue to inform and influence home dialysis programs, ultimately helping more patients succeed on home hemodialysis."

A key component of the Nx2me platform is the Nx2me iPad^® app, which is designed to increase patients' ease of use of home therapy by capturing treatment data and wirelessly sending it to their center after each treatment, thereby reducing the need for paper flow sheets. Dialysis center staff can access the treatment data, sent through a secured and encrypted web server, using the Nx2me Clinician Portal. The timely receipt of electronic flowsheets from the Nx2me app allows for early intervention to help reduce patient complications and hospitalizations. In addition, Nx2me integrates with center EMR systems to provide clinicians with treatment and billing information.

NxStage continues to enhance the capabilities of the Nx2me platform, introducing new features including picture sharing between patients and clinicians, and streaming video to enhance communication with NxStage Technical Support.

For more information about Nx2me and home hemodialysis with the NxStage System One, please visit www.NxStage.com.

The reported benefits of home hemodialysis (HHD) may not be experienced by all patients.

The NxStage System is a prescription device and, like all medical devices, involves some risks. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. When vascular access is exposed to more frequent use, infection of the site, and other access related complications may also be potential risks.  The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream, and blood loss due to clotting or accidental disconnection of the blood tubing set.

Home hemodialysis with the NxStage System during waking hours may not require a care partner, provided a physician and a qualified patient agree that solo home hemodialysis is appropriate. Patients performing nocturnal treatments are required to have a care partner. Care partners are trained on proper operation and how to get medical or technical help if needed.

Certain risks associated with hemodialysis treatment are increased when performing solo HHD because no one is present to help the patient respond to health emergencies. If patients experience needles coming out, blood loss, or very low blood pressure during solo HHD, they may lose consciousness or become physically unable to correct the health emergency.  Losing consciousness or otherwise becoming impaired during any health emergency while alone could result in significant injury or death. Additional ancillary devices and training are required when performing solo HHD.

Certain risks associated with hemodialysis treatment are increased when performing nocturnal therapy due to the length of treatment time and because therapy is performed while the patient and care partner are sleeping. These risks include, but are not limited to, blood access disconnects and blood loss during sleep, blood clotting due to slower blood flow and/or increased treatment time, and delayed response to alarms when waking from sleep.

Patients should consult their doctor to understand the risks and responsibilities of performing these therapies using the NxStage System.

About the NxStage System One 
The NxStage System One is a simple, flexible and portable hemodialysis system that provides a wide range of dialysis therapy options, including home, more frequent, solo, and nocturnal dialysis. Visit www.nxstage.com for more information on therapy options with the System One.

About NxStage Medical 
NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical technology company, headquartered in Lawrence, MA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products and services, please visit the Company's website at www.nxstage.com.

Forward-looking Statements 
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2018. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Media contact:  
Kristen K. Sheppard, Esq. 
ksheppard@nxstage.com

References:  
1. Data on file. 2018. NxStage Medical, Inc.  
2. Weinhandl E, Collins AJ. Relative risk of home hemodialysis attrition in patients using a telehealth platform. Hemodial Int. 2018;22(3):318-327.

View original content to download multimedia:http://www.prnewswire.com/news-releases/nxstage-announces-significant-increase-in-nx2me-connected-health-platform-adoption-300738675.html

SOURCE NxStage Medical, Inc.